When treating refractory kidney cancer, clinicians prioritize regimens offering the most durable initial response. They argue against “saving” effective drugs for later, as disease progression is traumatic for patients and many never successfully receive subsequent lines of therapy. The goal is long-term disease control now, not preserving theoretical future options.

The extreme effectiveness of frontline BEP chemotherapy makes it nearly impossible to replace. This forces novel drug development into the small, refractory patient population. This niche market makes it economically challenging for pharmaceutical companies to invest in large-scale trials, thus slowing innovation for new agents.

Unlike most trials that avoid patients who failed other therapies, Corvus intentionally included them, considering it a 'stacking deck against yourself'. This high-risk bet, based on their drug's unique mechanism, paid off by showing efficacy in a tough-to-treat population and demonstrating a lack of cross-resistance.

Developers often test novel agents in late-line settings because the control arm is weaker, increasing the statistical chance of success. However, this strategy may doom effective immunotherapies by testing them in biologically hostile, resistant tumors, masking their true potential.

A Phase II trial of cabozantinib in heavily pre-treated, relapsed/refractory germ cell tumors demonstrated a clinical benefit rate of 43.2%. This marks a significant breakthrough as the first non-chemotherapy agent to show meaningful activity in this chemo-veteran population, offering a new therapeutic avenue for patients with limited options beyond aggressive chemotherapy and stem cell transplant.

The O11 trial (Len-Belzutafan vs. Cabozantinib) presents the first randomized Phase 3 data for a VEGF/HIF inhibitor combination. Its results will be pivotal in determining if this more toxic doublet approach is justified over monotherapy for IO-refractory kidney cancer, weighing the magnitude of benefit against increased side effects.

Exploratory analysis shows that while patients with 100% PTEN loss have a much worse natural history than those with 90% loss, the therapeutic effect of capivasertib is stable across this spectrum. The drug effectively targets the pathway regardless of the magnitude of loss, making it a robust option for this entire subgroup.

Even when testing drugs in heavily pre-treated patients, clinical trials incorporate subtle biological selection criteria. For instance, the COMPASS trial excludes patients with visceral metastases, a tactic to enrich for a population more likely to respond and avoid the most aggressive disease subtypes.

The IMbark trial demonstrated that an ARPI (enzalutamide), either alone or with ADT, outperformed ADT monotherapy in high-risk patients. This pivotal finding raises the question of whether giving ADT alone in any setting, such as with radiation for localized disease, is now an outdated and inferior approach.